Becton Dickinson & Co. closed 3.20% below its 52-week high of $248.42, which the company achieved on March 28th.

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of ...

Authenticated data presented in the Rapid Diagnostics market report is based on findings of extensive primary and secondary research ...

Not-for-profit healthcare organisation Carilion Clinic is set to provide needle-free blood draws to patients leveraging Becton, Dickinson and Company’s (BD) blood collection device.

In a recent transaction, Shan David, Executive Vice President and Chief ISC Officer at Becton Dickinson & Co (NYSE:BDX), sold ...

Shana Neal, Executive Vice President and Chief People Officer at Becton Dickinson & Co (NYSE:BDX), recently sold shares in the company according to a regulatory filing. On January 21, Neal sold 787 ...

Becton, Dickinson's stock momentum is improving, but geopolitical risks and global headwinds warrant caution. Click here to ...

Gateway Investment Advisers LLC reduced its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by ...